首页> 外文期刊>Clinical ophthalmology >Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
【24h】

Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells

机译:有和没有苯扎氯铵的抗青光眼药物对培养的人角膜内皮细胞的毒性

获取原文
       

摘要

Purpose: The toxicity of antiglaucoma medications to ocular surface cells has been evaluated extensively; however, the toxicity to corneal endothelial cells (CECs) remains elusive. Our aim is to evaluate the toxicity of antiglaucoma medications to CECs using an in vitro toxicity assay.Methods: Primary cultures of human (H) CECs derived from eye bank specimens were established. Following exposure of HCECs to test solutions for 10, 30, or 60 minutes, or 48 hours, we measured cell viability using a WST-1 assay. Test solutions were diluted in culture media and included 0.5% Timoptol?, preservative-free 0.5% timolol maleate, 1% Trusopt?, preservative-free 1% dorzolamide, Travatan?, Travatan Z?, Xalatan?, and benzalkonium chloride (BAK). To assess cell viability, the value of the test culture well after treatment was expressed as a percentage of that of the control well. Toxicity of each solution was compared using the cell viability score (CVS).Results: After exposure to 10-fold dilutions of test solutions for 48 hours, HCEC viabilities were 48.5% for 0.5% Timoptol, 80.9% for preservative-free 0.5% timolol maleate, 47.0% for 1% Trusopt, 71.7% for preservative-free 1% dorzolamide, 55.5% for Travatan, 88.5% for Travatan Z, and 52.5% for Xalatan. Exposure to test solutions diluted 100-fold or more resulted in HCEC viabilities > 80%, with the exception of preservative-free 1% dorzolamide, which resulted in a viability of 72.0% at a dilution of 100-fold. Based on CVS, the order of cell viability was Travatan Z?≥ preservative-free timolol maleate = preservative-free dorzolamide > 0.5% Timoptol = 1% Trusopt > Travatan?≥ Xalatan. Assessment of the combined effect of drug and BAK revealed that latanoprost reduced the toxicity of BAK.Conclusion: Antiglaucoma eye drops produced HCEC toxicity that appeared to depend on the presence of BAK. Because dilution of the antiglaucoma solutions resulted in markedly lower HCEC toxicity, HCEC damage due to antiglaucoma medication may occur only in rare cases. The CVS was useful for comparison of the toxicity of the drugs.
机译:目的:已经广泛评估了抗青光眼药物对眼表细胞的毒性。然而,对角膜内皮细胞(CEC)的毒性仍然难以捉摸。我们的目的是使用体外毒性测定法评估抗青光眼药物对CEC的毒性。方法:建立源自眼库标本的人(H)CEC的原代培养物。在将HCEC暴露于测试溶液10、30或60分钟或48小时后,我们使用WST-1测定法测量了细胞活力。将测试溶液在培养基中稀释,并包括0.5%Timoptol ?、无防腐剂的0.5%timolol马来酸酯,1%Trusopt ?、无防腐剂的1%dorzolamide,Travatan?,Travatan Z?,Xalatan?和苯扎氯铵(BAK) 。为了评估细胞活力,将处理后测试培养孔的值表示为对照孔的值的百分比。结果:在暴露于10倍稀释的测试溶液中48小时后,HCEC的活性为0.5%的Timoptol为48.5%,不含防腐剂的0.5%timolol为80.9%。马来酸酯,1%Trusopt占47.0%,不含防腐剂的1%多唑胺占71.7%,Travatan占55.5%,Travatan Z占88.5%,Xalatan占52.5%。暴露于稀释100倍或更多倍的测试溶液会导致HCEC活力> 80%,不含防腐剂的1%多唑胺会导致HCEC活力,稀释100倍时会产生72.0%的活力。基于CVS,细胞活力的顺序为:TravatanZ≥≥不含防腐剂的马来酸替莫洛尔=不含防腐剂的多佐胺> 0.5%丁草酚= 1%Trusopt>Travatan≥Xalatan。对药物和BAK联合作用的评估表明,拉坦前列素降低了BAK的毒性。结论:抗青光眼滴眼液产生的HCEC毒性似乎取决于BAK的存在。由于抗青光眼溶液的稀释导致HCEC毒性显着降低,因此仅在极少数情况下可能会发生因抗青光眼药物引起的HCEC损害。 CVS可用于比较药物的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号